Edinburgh Research Explorer

FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)17
JournalJournal for immunotherapy of cancer
Publication statusPublished - 21 Feb 2017


Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and colleagues identified a key role for FAK in regulating the composition of the fibrotic and immuno-suppressive pancreatic tumour niche, and showed that FAK inhibitors can be used in combination with immune checkpoint blockade and gemcitabine chemotherapy to significantly delay pancreatic tumour progression. This study further supports the use of FAK inhibitors in combination with immunotherapy.

    Research areas

  • FAK, Immunotherapy, Checkpoint Blockade, Pancreatic Cancer

Download statistics

No data available

ID: 33060426